Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2022-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Hyundai Bioscience. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation material provided to shareholders to inform them of upcoming meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Hyundai Bioscience. It details the agenda for the 22nd Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. This document is a formal proxy statement sent to shareholders to provide information and request votes for the upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2022-03-14 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the agenda items, candidate information for board elections, and financial summaries to inform shareholders before they cast their votes. This fits the definition of a Proxy Solicitation & Information Statement.
2022-03-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Hyundai Bioscience) disclosing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting preliminary financial results before the final audited annual report is published. Since it provides key financial highlights and reasons for the variance, it fits the definition of an Earnings Release (ER). FY 2021
2022-02-24 Korean
투자판단관련주요경영사항(코로나-19 치료제 CP-COV03의 국내 제1상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by Hyundai Bioscience regarding the results of a Phase 1 clinical trial for a COVID-19 treatment (CP-COV03). It details the trial methodology, safety results, pharmacokinetic data, and future plans. In the context of Korean corporate filings (DART system), this is classified as a 'Major Management Matter' (주요경영사항) disclosure, which serves as a regulatory announcement of material corporate events. Since it does not fit into specific categories like financial reports or shareholder meetings, it falls under the general regulatory filing category.
2022-02-09 Korean
투자판단관련주요경영사항(COVID-19 치료제 CP-COV03의 제2상 임상시험계획 신청서 제출)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Hyundai Bioscience regarding the submission of a Phase 2 clinical trial application for a COVID-19 treatment (CP-COV03) to the Ministry of Food and Drug Safety. It is a specific disclosure of a material business event (major management matter) related to clinical trials. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2022-01-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.